Showing 3971-3980 of 8681 results for "".
- ISHRS to Host 32nd World Congress in Denver This Monthhttps://practicaldermatology.com/news/ishrs-host-32nd-world-congress-denver-month/2468370/From refinements in hair restoration surgical techniques to understanding the psychological and physiological aspects of hair loss, the latest research and concepts in hair growth and restoration will be presented by some of the world’s most renowned hair restoration experts when they convene in
- TRuE AD3: Ruxolitinib Safety and Efficacy Confirmed in Children with Atopic Dermatitishttps://practicaldermatology.com/news/52-week-study-validates-ruxolitinibs-safety-and-efficacy-in-children-with-ad/2468353/Ruxolitinib cream (RUX) demonstrated long-term safety and efficacy in children aged 2 to 11 with mild-to-moderate atopic dermatitis (AD), with over 60% of patients achieving clear or nearly clear skin, according to updated data presented recently at the 2024 European Academy of Dermatology and Ve
- Triple-Combination Acne Treatment Shows Equal Efficacy Across Sexeshttps://practicaldermatology.com/news/triple-combination-acne-treatment-shows-equal-efficacy-across-sexes/2468352/A post hoc analysis of two phase 3 studies showed clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) had s
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- DELTA FORCE: Delgocitinib Cream Superior for Chronic Hand Eczema Treatmenthttps://practicaldermatology.com/news/delta-force-delgocitinib-cream-superior-chronic-hand-eczema-treatment/2468306/New data from the DELTA FORCE trial presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress suggests that delgocitinib cream showed superior efficacy and safety compared to oral alitretinoin for the treatment of chronic hand eczema (CHE). “The completion of th
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan
- Kenvue to Present New Data Sets at EADV Congresshttps://practicaldermatology.com/news/kenvue-present-new-data-sets-eadv-congress/2468301/Kenvue announced the presentation of seven new data sets at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will feature Kenvue’s Aveeno and Neutrogena brands, “demonstrating the key to improved skin and hair outcome
- New Photoprotection Data at EADV Congresshttps://practicaldermatology.com/news/new-photoprotection-data-eadv-congress/2468300/Kenvue announced the presentation of two new data sets relating to photoprotection at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will demonstrate "the key to improved skin and hair outcomes through proactive use
- Roflumilast Cream Shows Consistent Results in AD Across Skin Typeshttps://practicaldermatology.com/news/roflumilast-cream-shows-consistent-results-ad-across-skin-types/2468298/Newly published pooled analyses of the INTEGUMENT trials suggest that ZORYVE (roflumilast) cream 0.15% showed significant improvements in atopic dermatitis (AD) symptoms, regardless of race, ethnicity, or Fitzpatrick skin type. Results from the studies showed that higher percentages of pat